New modelling in Emerging Infectious Diseases projects how Mycobacterium tuberculosis infection and disease could evolve from 2024 to 2050 among migrants to low-incidence countries under different transmission-reduction scenarios, while WHO's 2024 Global Tuberculosis Report shows the world far off End TB targets. Together they imply a long tail of latent infection and persistent disease, even as incidence slowly falls. The next half-century of TB control will hinge on undernutrition, mobility, housing, new tools, and sustained political will.
Verdict: Emerging Infectious Diseases modelling suggests that, under status quo trends, substantial latent M. tuberculosis infection and non-trivial TB risk will persist among migrants to low-incidence countries through 2050, with faster annual reductions in infection yielding sizeable benefits (EID, 2026-02-27).([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1340_article?utm_source=openai)) WHO's 2024 Global Tuberculosis Report shows global TB incidence has fallen only around 9 percent since 2015, far short of the 50 percent reduction targeted by 2025 (WHO, 2024-10-29).([who.int](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024?utm_source=openai)) Independent analyses argue that End TB goals are unattainable without strong action on undernutrition, displacement, and homelessness, which remain under-addressed (BMC Public Health, 2024-01-15).([bmcpublichealth.biomedcentral.com](https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-024-18400-5?utm_source=openai))
New TB vaccines for adolescents and adults, alongside shorter preventive regimens and expanded social protection, are rolled out at scale in high-burden settings by the early 2030s. Annual declines in incidence approach or exceed 10 percent in many countries, substantially narrowing the gap to End TB goals. While elimination is not achieved, TB's role as a leading infectious killer is decisively ended within two decades.
Incremental improvements in diagnostics, treatment, and program coverage continue, but funding and political attention remain uneven. Incidence falls slowly, especially in high-burden countries facing undernutrition, weak primary care, and rapid urbanisation. TB remains a major cause of death in vulnerable groups through at least the 2030s, even as some low-incidence countries edge closer to elimination benchmarks.
Economic shocks, conflicts, and climate-driven displacement undermine TB programs and worsen undernutrition. Drug-resistant TB expands in pockets where treatment interruption is common. Global attention shifts to new pathogens, leaving TB services underfunded. Incidence plateaus or rises in several regions, and by mid-century TB remains entrenched in fragile settings, with large health and economic burdens.
A paradigm-shifting host-directed therapy or broadly effective aerosol vaccine dramatically reduces infectiousness and progression from infection to disease. If deployed widely, this could compress decades of expected decline into a single generation. However, inequitable access or biological surprises, such as strain evolution, might limit impact or create new challenges, making outcomes highly path-dependent.
Developments: Within a year, more countries integrate updated WHO estimates into national TB strategies, focusing on catching up after pandemic-related setbacks. Programmes in low-incidence countries examine immigrant TB risk using the new modelling to refine screening and preventive treatment policies. Donors and governments reassess funding gaps in light of documented shortfalls relative to End TB trajectories.
Risks: Short-term budget pressures could favour visible, acute health crises over chronic TB investments. Screening of migrants and marginalised groups may be tightened in ways that stigmatise or deter care-seeking rather than support it. Overconfidence in current tools might delay serious investment in new vaccines and host-directed therapies.
Outlook: Over the first year, the modelling mainly influences planning documents and technical discussions. The key risk is that recognition of missed targets does not translate into materially higher or smarter investment. Responsiveness to the new evidence will set the tone for the coming decade.
Developments: By two years, more low-incidence countries adopt risk-stratified screening and preventive treatment strategies for recent arrivals from high-burden settings, guided by imported-infection projections. High-burden countries refine subnational plans that prioritise districts with high incidence, undernutrition, and poor housing. Pilot programmes expand cash transfers or food support linked to TB care in several settings.
Risks: If preventive treatment is expanded without robust adherence support, resistance concerns could grow. Political narratives that overemphasise migrants as TB sources may exacerbate xenophobia and distract from domestic determinants. Social protection pilots may prove difficult to sustain or scale without strong evidence of cost-effectiveness and political backing.
Outlook: Two years in, strategies become more targeted but remain constrained by resources and governance. The main question is whether social and biomedical interventions are integrated or pursued in parallel silos. Success depends on protecting rights while closing infection and care gaps.
Developments: Within three years, late-stage trials of one or more new TB vaccines report results, clarifying the medium-term role of vaccination in achieving faster declines. Shorter all-oral regimens for drug-susceptible and resistant TB are more widely available, simplifying care logistics. Global TB initiatives publish clearer investment cases that quantify the economic costs of missing End TB milestones.
Risks: If vaccine results are modest or mixed, political enthusiasm for TB innovation may wane. Programmes may experience fatigue as incremental progress fails to match ambitious rhetoric, risking staff turnover and lower quality. Competing global priorities, including climate adaptation and other emerging infections, could crowd out TB finances.
Outlook: At three years, scientific signals and funding decisions start to crystallise medium-term TB futures. A balanced response requires neither despair in the face of imperfect tools nor complacency with slow declines. Strategic alignment of innovation, service delivery, and social policy is still possible but not guaranteed.
Developments: Five years on, regions that combine robust health systems, social protection, and focused TB investments show steeper incidence declines and lower mortality. Some high-burden countries achieve double-digit annual reductions in targeted districts. Others, especially those affected by conflicts, climate shocks, or governance crises, lag badly, with TB increasingly concentrated in fragile contexts.
Risks: Persistent regional divergence may normalise high TB burden as a "problem of fragile states," weakening global solidarity and investment. Drug-resistant TB can entrench in poorly performing areas, posing long-term cross-border risks. Urban megacities with large informal settlements may remain hot spots even in otherwise improving countries.
Outlook: In five years, the TB epidemic becomes more geographically and socially concentrated. This creates opportunities for focused efforts but also risks of neglect. Whether the world chooses solidarity or segmentation will shape later decades.
Developments: Over a decade, urbanisation, climate change, and migration reshape TB risk landscapes. Crowded, poorly ventilated housing in growing cities becomes a dominant locus of transmission in many countries. Health systems that integrate TB with primary care, noncommunicable disease management, and social services manage to keep declines on track. New vaccines, if successful and equitably deployed, begin to influence cohort-level infection patterns.
Risks: Climate shocks and food insecurity could repeatedly disrupt TB programmes and worsen undernutrition, particularly in rural and peri-urban areas. If vaccines are rolled out inequitably, benefits may accrue mainly to relatively better-off populations, widening gaps. Surveillance systems may struggle to keep pace with mobile populations and informal housing arrangements.
Outlook: Ten years from now, TB control is inseparable from urban planning, climate adaptation, and social policy. Countries that treat TB as a cross-sectoral challenge are most likely to see sustained declines. Others risk repeated setbacks and chronic hotspots.
Developments: Two decades out, most people infected in the high-incidence years of the early 21st century have either cleared infection, developed disease, or aged into lower-risk groups, reducing the latent reservoir. If vaccines and preventive treatment were scaled, the average age at infection has shifted upward or infection risks have declined. TB incidence is much lower in many places, but small, stubborn pockets remain where determinants were never fully addressed.
Risks: Residual hotspots, often linked to prisons, mines, refugee camps, and informal settlements, may continue to seed outbreaks. Comorbidities such as diabetes and HIV, alongside aging populations, could sustain TB risk among specific groups. Global attention may drift away from TB once numbers fall, leaving underfunded systems vulnerable to resurgence or drug resistance.
Outlook: At twenty years, TB may be substantially reduced but not gone. The world faces a choice between long-term stewardship to finish the job or complacency that allows embers to smoulder. Investments in surveillance and social determinants become even more important as case numbers drop.
Developments: Over half a century, TB could plausibly transition from a leading killer to a rare, outbreak-prone disease in most regions, remembered much like smallpox in the public imagination but still demanding vigilance. Alternatively, if social and political determinants remain unaddressed in large parts of the world, TB could persist as a chronic, regionalised burden that periodically re-enters global consciousness. The modelling work of the 2020s will be seen as either a warning heeded or one of many ignored alerts.
Risks: Societies may undervalue maintaining TB capacity once caseloads shrink, making them ill-prepared for future resurgences or related mycobacterial threats. If drug resistance is not controlled, pockets of nearly untreatable TB could pose biosecurity and ethical dilemmas. Historical narratives that frame TB solely as a past victory may obscure ongoing responsibilities to high-burden communities.
Outlook: Fifty years from now, TB's status will reveal how seriously the world treated inequality, housing, nutrition, and sustained public health investment. A future where TB is truly rare is technically feasible but politically demanding. The alternative is an extended, avoidable coexistence with a preventable disease.